Kimura, Shun-ichi http://orcid.org/0000-0001-9827-8526
Tamaki, Masaharu
Okinaka, Keiji
Seo, Sachiko
Uchida, Naoyuki
Igarashi, Aiko
Ozawa, Yukiyasu
Ikegame, Kazuhiro
Eto, Tetsuya
Tanaka, Masatsugu
Shiratori, Souichi
Nakamae, Hirohisa
Sawa, Masashi
Kawakita, Toshiro
Onizuka, Makoto
Fukuda, Takahiro
Atsuta, Yoshiko
Kanda, Yoshinobu
Nakasone, Hideki
Article History
Received: 1 February 2021
Accepted: 27 August 2021
First Online: 7 September 2021
Declarations
:
: This study was approved by the data management committee of the Japanese Society for Transplantation and Cellular Therapy and by the institutional review board of Jichi Medical University Saitama Medical Center (Saitama, Japan). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: The Transplant Registry Unified Management Program (TRUMP) database of the Japanese Society for Transplantation and Cellular Therapy and the Japanese Data Center for Hematopoietic Cell Transplantation includes physician-reviewed data. Observational studies based on the TRUMP database are performed with informed consent.
: Shun-ichi Kimura has received a grant from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP20K17406 and received personal fees from Asahi Kasei, Sumitomo Dainippon Pharma, MSD, Astellas, Pfizer, Kyowa Kirin, Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb, Celgene, Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Nippon Kayaku. Sachiko Seo has received personal fees from Janssen Pharmaceuticals. K.K. Hirohisa Nakamae has received honoraria from Amgen Astellas BioPharma K.K., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Celgene Corporation, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., Japan Blood Products Organization, Nippon Shinyaku Co., Ltd., Novartis, Pfizer Japan Inc., Bristol Myers Squibb, Shire Japan KK, and Ono Pharmaceutical Co., Ltd. and received grants from Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Novartis, Bristol Myers Squibb, and PPD-SNBL K.K. Masashi Sawa has received personal fees from Chugai, Pfizer, Astellas, Nippon-Shinyaku, Ono, MSD, Bristol Myers Squibb, Kyowa Hakko Kirin, Asahi Kasei, Novartis, Eisai, Otsuka, Sumitomo Dainippon, Sanofi, Takeda, Celgene, Mochida, Shire, and Mundipharma. Yoshinobu Kanda has received honoraria from Merck Sharp & Dohme, Astellas, Sumitomo Dainippon Pharma, Chugai Pharmaceutical Co., Ltd., and Pfizer, and received research funding from Sumitomo Dainippon Pharma, Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astellas, Kyowa Kirin, Takeda Pharmaceutical Company Limited., Ono Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd. Hideki Nakasone has received grants from Japan Agency for Medical Research and Development and Japan Society for the Promotion of Science, and received personal fees from Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol Myers Squibb, Celgene, Pfizer, Novartis, Janssen Pharmaceutical K.K., Eisai, Chugai Pharmaceutical, and Nippon Shinyaku. Other authors: none to declare.